• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

How Frequently Should We Re-Screen Following a Negative HPV result?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Studies have demonstrated higher sensitivity for high-risk HPV tests vs cytology
  • Zorzi et al. (BJOG, 2017) compared the results from an initial negative HPV test with re-screening CIN2+ results at 3 year follow-up

METHODS:

  • Population-based cohort study
    • Women aged 25-64 years who received an HPV test
  • Protocol
    • Initial screen: Both HPV testing (Hybrid Capture 2; Qiagen) and conventional smear (except for women who had never been sexually active, who underwent a Pap smear alone)
      • HPV-: re-screening at 3 years
    • If HPV+, cyto ‘triage’ performed
      • HPV+/cyto-: re-screening at 1 year
      • HPV+/cyto+: referred for colposcopy
    • If still HPV+at 1 year or was positive at the 3 year rescreening, patient was referred for colposcopy
  • Main outcomes
    • Participation rate | Positivity at HPV and at triage | Referral rate to colposcopy | PPV for CIN2+ | Detection rate for CIN2+

RESULTS:

  • 48,751 initially screened
    • 29,694 were HPV- and therefore re-invited for 3 year follow screening (second screening)
  • Compared with the first screening, the second screening showed significant reduction of
    • HPV positivity: RR 0.55 (95% CI 0.51–0.60)
    • Referral rate to colposcopy: RR 0.47 (95% CI 0.41–0.53)
    • CIN2+ detection rate: RR 0.24 (95% CI 0.13–0.39)
    • PPV: for CIN2+ at colposcopy: RR 0.51 (95% CI 0.29–0.87)
  • PPV for CIN2+
    • First screening: PPV 14.9%
    • Second screening: PPV 7.7%
    • Numbers of colposcopies needed to detect one CIN2+
      • First screening: 8.5
      • Second screening: 17.6
    • No invasive cancers were detected at the second screening or at 1 year repeat of the first screening
      • There were 6 cancers detected at baseline

CONCLUSION:

  • Authors acknowledge that PPV is based on local HPV infection rates and, therefore, data may not be generalizable
  • They conclude that low frequency of disease and low PPV demonstrate that 3 years may be too short a time interval for HPV screening follow up

Learn More – Primary Sources:

A 3 year interval is too short for re-screening women testing negative for human papillomavirus: a population-based cohort study

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone

Learn More  »

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Cervical Cancer Screening Guidelines: The Role of Pap and HPV
Guidance Update: Professional Organizations Align on Cervical Cancer Screening
HPV Vaccine Recommendations Including Guidance for Ages 27 to 45
HPV Testing vs PAP Smear: Results of the HPV FOCAL Trial
What to Do with a Normal Pap but Positive HPV, ASC-US, LSIL and ASC-H

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site